Clinical trial · Observational
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer Using Clinical Histopathological and Biological Markers
NCT03121768CI-TRIAL-00027582unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high risk groups and including all potential and highly prognostic factors.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BCG | — | UNRESOLVED | — |
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Oncology | — | UNRESOLVED | — |
| Progression | — | UNRESOLVED | — |
| Recurrence | — | UNRESOLVED | — |
| Superficial Bladder Cancer | Non-Muscle Invasive Bladder Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Construct a new prognostic model for the prediction of recurrence and progression of NMIBC
- timeFrame
- 2 years
- description
- Outcome Measure by counting and cmparing number of patients surviving for two year without tumor recurrence or progression to muscle invasive bladder cancer
Secondary outcomes (2)
- measure
- cancer-specific survival (CSS) after treatment of NMIBC
- timeFrame
- 5 years
- description
- Outcome Measure by counting and comparing number of patients surviving for five year without tumor. Mortality cases will be counted if oncology is the cause of mortality
- measure
- overall survival (OS) after treatment of NMIBC
- timeFrame
- 5 years
- description
- Outcome Measure by conting and comparing number of patients surviving for five year without tumor. Mortality cases will be counted if the cause of mortality is other than oncology
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: -Patient with NMIBC Exclusion Criteria: * Refuse to complete study requirements * Contraindication to BCG therapy * Muscle invasive disease
References
Publications (0)
Data not yet available
No reference posted for this study.